These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25851308)

  • 1. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.
    Martín M; González-Rivera M; Morales S; de la Haba-Rodriguez J; González-Cortijo L; Manso L; Albanell J; González-Martín A; González S; Arcusa A; de la Cruz-Merino L; Rojo F; Vidal M; Galván P; Aguirre E; Morales C; Ferree S; Pompilio K; Casas M; Caballero R; Goicoechea U; Carrasco E; Michalopoulos S; Hornberger J; Prat A
    Curr Med Res Opin; 2015 Jun; 31(6):1129-37. PubMed ID: 25851308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
    Hequet D; Callens C; Gentien D; Albaud B; Mouret-Reynier MA; Dubot C; Cottu P; Huchon C; Zilberman S; Berseneff H; Foa C; Salmon R; Roulot A; Lerebours F; Salomon A; Ghali N; Morel P; Li Q; Cayre A; Guinebretière JM; Hornberger J; Penault-Llorca F; Rouzier R
    PLoS One; 2017; 12(10):e0185753. PubMed ID: 29045452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
    Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
    Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.
    Gligorov J; Pivot XB; Jacot W; Naman HL; Spaeth D; Misset JL; Largillier R; Sautiere JL; de Roquancourt A; Pomel C; Rouanet P; Rouzier R; Penault-Llorca FM;
    Oncologist; 2015 Aug; 20(8):873-9. PubMed ID: 26112003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1).
    Ohnstad HO; Blix ES; Akslen LA; Gilje B; Raj SX; Skjerven H; Borgen E; Janssen EAM; Mortensen E; Brekke MB; Falk RS; Schlichting E; Boge B; Songe-Møller S; Olsson P; Heie A; Mannsåker B; Vestlid MA; Kursetgjerde T; Gravdehaug B; Suhrke P; Sanchez E; Bublevic J; Røe OD; Geitvik GA; Halset EH; Rypdal MC; Langerød A; Lømo J; Garred Ø; Porojnicu A; Engebraaten O; Geisler J; Lyngra M; Hansen MH; Søiland H; Nakken T; Asphaug L; Kristensen V; Sørlie T; Nygård JF; Kiserud CE; Reinertsen KV; Russnes HG; Naume B
    ESMO Open; 2024 Jun; 9(6):103475. PubMed ID: 38838499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
    Leung RC; Yau TC; Chan MC; Chan SW; Chan TW; Tsang YY; Wong TT; Chao C; Yoshizawa C; Soong IS; Kwan WH; Kwok CC; Suen JS; Ngan RK; Cheung PS
    Clin Breast Cancer; 2016 Oct; 16(5):372-378. PubMed ID: 27105769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
    Albanell J; Svedman C; Gligorov J; Holt SD; Bertelli G; Blohmer JU; Rouzier R; Lluch A; Eiermann W
    Eur J Cancer; 2016 Oct; 66():104-13. PubMed ID: 27544930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
    Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
    Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
    Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew-Shue M; Chao C; Eisen A
    Oncologist; 2018 Jul; 23(7):768-775. PubMed ID: 29371476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of 21-gene recurrence score on chemotherapy decisions for patients with estrogen receptor-positive, epidermal growth factor receptor 2-negative and lymph node-negative early stage-breast cancer].
    Mao Y; Chen XS; Liang Y; Wu JY; Huang O; Zong Y; Fang Q; He JR; Zhu L; Chen WG; Li YF; Lin L; Fei XC; Shen KW
    Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):502-508. PubMed ID: 28728295
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
    de Boer RH; Baker C; Speakman D; Chao CY; Yoshizawa C; Mann GB
    Med J Aust; 2013 Aug; 199(3):205-8. PubMed ID: 23909545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
    Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
    Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
    J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
    Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
    Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.
    Alvarado MD; Prasad C; Rothney M; Cherbavaz DB; Sing AP; Baehner FL; Svedman C; Markopoulos CJ
    Adv Ther; 2015 Dec; 32(12):1237-47. PubMed ID: 26610383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
    Fernandez-Martinez A; Pascual T; Perrone G; Morales S; de la Haba J; González-Rivera M; Galván P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; Prat A; Martin M
    Oncotarget; 2017 Mar; 8(13):21930-21937. PubMed ID: 28423537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes.
    Laenkholm AV; Jensen MB; Eriksen JO; Buckingham W; Ferree S; Nielsen TO; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):44-50. PubMed ID: 29202609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
    Eiermann W; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Schneeweiss A; Markmann S; Eggemann H; Hilfrich J; Jackisch C; Witzel I; Eidtmann H; Bachinger A; Hell S; Blohmer J
    Ann Oncol; 2013 Mar; 24(3):618-24. PubMed ID: 23136233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
    Lænkholm AV; Jensen MB; Eriksen JO; Rasmussen BB; Knoop AS; Buckingham W; Ferree S; Schaper C; Nielsen TO; Haffner T; Kibøl T; Møller Talman ML; Bak Jylling AM; Tabor TP; Ejlertsen B
    J Clin Oncol; 2018 Mar; 36(8):735-740. PubMed ID: 29369732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
    Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
    Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.